ClinConnect ClinConnect Logo
Search / Trial NCT02952365

Tissue Sealant Use in LASIK Enhancement Surgery

Launched by STANFORD UNIVERSITY · Oct 31, 2016

Trial Information

Current as of June 29, 2025

Completed

Keywords

Lasik, Ingrowth, Tissue Sealant

ClinConnect Summary

Participants will have a comprehensive eye examination once they express an interest in the study. This includes a slit lamp examination of the front of the eye and a dilated fundoscopic examination of the back of the eye. If there is any pathology noted that would exclude the participant from the study, then the participant will be informed and given an appropriate referral. If the participant is deemed appropriate for the study after a comprehensive examination included computerized videokeratography, then they can be enrolled. The participant will undergo LASIK flap lift eye surgery.

Ti...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects age 21 and older
  • Subjects with healthy eyes
  • Subjects who have previously undergone LASIK surgery
  • Subjects with residual refractive error.
  • Exclusion Criteria:
  • Subjects under the age of 21.
  • Subjects with excessively thin corneas.
  • Subjects with topographic evidence of keratoconus.
  • Subjects with ectatic eye disorders.
  • Subjects with autoimmune diseases.
  • Subjects who are pregnant or nursing.

About Stanford University

Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.

Locations

Palo Alto, California, United States

Patients applied

0 patients applied

Trial Officials

Edward E Manche, MD

Principal Investigator

Stanford University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials